Celea Therapeutics’ $180M financing will support a Phase 3 IPF drug trial comparing deupirfenidone with Esbriet.

Researchers have found that a decrease in scar-generating cell death called ferroptosis may be a mechanism that drives IPF.

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their main goals, showing that the inhalation therapy significantly outperformed a ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

There is no cure for pulmonary fibrosis (PF), but many therapies are in the pipeline that may be able to slow disease progression, manage symptoms, and improve quality of life for patients. Some of ...

A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian is working to develop a first-in-class group of small molecules ...

Families will gather this week to celebrate Thanksgiving here in the U.S. But how do you safely navigate a large family gathering when colds, the flu, and COVID-19 are all circulating? After I ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Living with a chronic and progressive disease like pulmonary fibrosis (PF) can be challenging, and there are many issues a person with PF needs to consider, including lifestyle changes, coping with ...

Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, ...